COVID-19 antibody responses in patients with CLL/lymphoma and healthy controls. (A) The IgG N antibody responses at baseline, time of dose 2, and 28 days after vaccination for the healthy cohort (red) and CLL/lymphoma cohort (blue). Low magnitudes at all time points demonstrate no prior history of natural infection or infection with COVID-19 during the study. (B) IgG S antibody titers in healthy cohort (red) (n = 23), as compared with the CLL/lymphoma cohort (blue) (n = 23). (C) The magnitude of IgG S antibody for patients who received CD20 therapy in the last 12 months (blue) (n = 6), as compared with those who received CD20 beyond 12 months (red) (n = 9). (D) IgG S antibody responses for the healthy cohort (red) (n = 23), as compared with patients with CLL/lymphoma who were treatment-naive (blue) (n = 5). The dotted horizontal line in panels B-D at 1.07 is an internally validated threshold that marks a positive or negative antibody response. The black error bars denote median with a 95% confidence interval AEB, average enzymes per bead.